NA
EBS icon

NewEdge Advisors’s Emergent Biosolutions EBS Stock Holding History

NewEdge Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-586
Closed -$5.6K – 4012
2024
Q4 		$5.6K Buy
+586
New +$5.38K ﹤0.01% 3209
2023
Q1 		– Sell
-135
Closed -$1.59K – 3608
2022
Q4 		$1.59K Buy
+135
New +$2.09K ﹤0.01% 2897

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NewEdge Advisors's EBS Position: Q1 2025 in Review

NewEdge Advisors sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 586 shares — an estimated $5.6K sold.

NewEdge Advisors first reported a position in EBS in Q4 2022 and held it in 2 quarters. The position peaked at $5.6K in Q4 2024. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

  • NewEdge Advisors reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
  • NewEdge Advisors sold 586 Emergent Biosolutions shares in Q1 2025, an estimated $5.6K.
  • NewEdge Advisors first reported a position in Emergent Biosolutions in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's Emergent Biosolutions position peaked at $5.6K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.